Descripción
Invitrocue is a world-class innovative life sciences company listed on the Australian Stock Exchange with Ticker code IVQ. They specialise in developing ground-breaking 3D cell-based models derived from liver and tumour tissues.
Their proprietary testing methods provide valuable insights into liver toxicology, infectious diseases and oncology.
By enabling assessments of the best ways for drugs to be developed, we impart to the industry valuable knowledge in creating better, faster and more affordable disease treatments, working towards the company’s goal of creating a healthier society by providing patients with the best possible care.
Invitrocue have also developed the propriety Onco-PDOTM (Patient-Derived Organoid) test, which goes the next step to personalised cancer treatment. With these results, physicians can prescribe the most appropriate treatment regime that suits your particular type of cancer.
Their proprietary testing methods provide valuable insights into liver toxicology, infectious diseases and oncology.
By enabling assessments of the best ways for drugs to be developed, we impart to the industry valuable knowledge in creating better, faster and more affordable disease treatments, working towards the company’s goal of creating a healthier society by providing patients with the best possible care.
Invitrocue have also developed the propriety Onco-PDOTM (Patient-Derived Organoid) test, which goes the next step to personalised cancer treatment. With these results, physicians can prescribe the most appropriate treatment regime that suits your particular type of cancer.
